US EditionPublished • loading... • Updated
Oral Semaglutide Does Not Halt Alzheimer's Disease in Phase 3 Trials
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Copenhagen – Daily oral administration of the GLP-1 agonist semaglutide did not halt the progression of dementia in people with Alzheimer's disease in two Phase 3 trials. However, some biomarkers of the disease did improve. The manufacturer, Novo Nordisk, has now announced the discontinuation of the evoke and evoke+ trials...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
